ASCO22 - PRADO: gunstige uitkomst responsgedreven therapie bij vroeg melanoom

Prof. dr. Christian Blank, hoogleraar Interne Geneeskunde in het Leids Universitair Medisch Centrum en werkzaam in het Antoni van Leeuwenhoek te Amsterdam, bespreekt de PRADO-studie die hij presenteerde tijdens de 2022 ASCO Annual Meeting. Aan bod komen onder andere de OpACIN-neo studie die ten grondslag ligt aan de PRADO-studie, de studieresultaten en de klinische implicaties voor patiënten met stadium 3-melanoom.

Episode metadata supplied by the publisher feed · Published Jun 9, 2022

Embed this episode

Attribution link and audio player

Ready to play

ASCO22 - PRADO: gunstige uitkomst responsgedreven therapie bij vroeg melanoom

0:00 8:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncologie.nu?

This episode is 8 minutes long.

When was this Oncologie.nu episode published?

This episode was published on June 9, 2022.

Can I download this Oncologie.nu episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!